BiotechTubeBiotechTube
Home/Pipeline/Trodelvy

Trodelvy

Breast cancer

CommercialActive

Key Facts

Indication
Breast cancer
Phase
Commercial
Status
Active
Company
Royalty Pharma

About Royalty Pharma

Founded in 1996, Royalty Pharma pioneered the royalty pharma asset class by providing non-dilutive capital to pharmaceutical innovators. The company has deployed over $19 billion to acquire royalty interests in leading medicines across multiple therapeutic areas. As a publicly-traded company on NASDAQ, Royalty Pharma generates revenue from royalty payments on successful drugs while helping fund the next generation of medical breakthroughs.

View full company profile

Therapeutic Areas

OncologyImmunologyNeurologyRespiratoryRare DiseasesInfectious Disease

Other Breast cancer Drugs

DrugCompanyPhase
Verzenio (abemaciclib)Eli LillyApproved
Pan-mutant-selective PI3Kα inhibitorNovartisAcquisition
Trastuzumab biosimilar (IBI306)Innovent BiologicsPhase 3
Ogivri (trastuzumab biosimilar)ViatrisApproved
Trastuzumab BiosimilarDr. Reddy's LaboratoriesApproved
Biosimilar TrastuzumabCiplaCommercial
Ogivri (Trastuzumab)BioconApproved
TamoxifenNatco PharmaApproved
ARV-027ArvinasPhase 1
Prognostic Genomic TestsEurobio ScientificCommercial
SelinexorKaryopharm TherapeuticsClinical Trials
ATNM-400Actinium PharmaceuticalsPreclinical